sorafenib has been researched along with gw 3965 in 3 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (gw 3965) | Trials (gw 3965) | Recent Studies (post-2010) (gw 3965) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 235 | 0 | 164 |
Protein | Taxonomy | sorafenib (IC50) | gw 3965 (IC50) |
---|---|---|---|
Alpha-glucosidase MAL32 | Saccharomyces cerevisiae S288C | 4.8 | |
Oxysterols receptor LXR-beta | Homo sapiens (human) | 0.47 | |
Oxysterols receptor LXR-alpha | Homo sapiens (human) | 0.5691 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 2 (66.67) | 2.80 |
Authors | Studies |
---|---|
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Chen, Y; Dai, F; Gu, T; Jiang, H; Li, K; Liang, Z; Liu, Y; She, J; Tang, L; Zhan, Z; Zhou, X | 1 |
Cai, X; Chen, J; Ji, L; Jiang, S; Liang, X; Liang, Y; Lin, C; Lin, Z; Pan, Y; Tao, L; Wan, Z; Xia, S; Xu, J | 1 |
3 other study(ies) available for sorafenib and gw 3965
Article | Year |
---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
LXR-Mediated Regulation of Marine-Derived Piericidins Aggravates High-Cholesterol Diet-Induced Cholesterol Metabolism Disorder in Mice.
Topics: Animals; Cholesterol; Cholesterol, Dietary; Diet, High-Fat; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Liver X Receptors; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Pericarditis; Structure-Activity Relationship; Tumor Cells, Cultured | 2021 |
LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.
Topics: Animals; Benzoates; Benzylamines; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Karyopherins; Liver Neoplasms; Liver X Receptors; Male; Mice; MicroRNAs; Middle Aged; Neoplasm Transplantation; Receptor, IGF Type 1; Sorafenib; Survival Analysis | 2020 |